Neurology Central

Analysis of three studies looks at the role of octagam® for chronic inflammatory demyelinating polyneuropathy patients

Our partner journal, Neurodegenerative Disease Management, recently published the article, ‘Octagam® for chronic inflammatory demyelinating polyneuropathy: results from three observational studies’, presenting data from three studies of a Post-Authorization Safety Surveillance (PASS) program for the subset of patients receiving octagam® 5% or 10% for chronic inflammatory demyelinating polyneuropathy (CIDP). Find out more in our summary below from the journal’s Commissioning Editor, Laura Dormer, or read the full article for free here
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.